Objective: Lung adenocarcinoma (LUAD) is a highly heterogeneous tumor. Tumor mutations
and the immune microenvironment play important roles in LUAD development and …

Lung cancer is one of the most common malignant tumors, and ranks high in the list of
mortality due to cancers. Lung adenocarcinoma (LUAD) is the most common subtype of lung …

Lung adenocarcinoma (LUAD), the most common non‐small‐cell lung cancer, is
characterized by a dense lymphocytic infiltrate, which indicates that the immune system …

Background Immune therapy has become first-line treatment option for patients with lung
cancer, but some patients respond poorly to immune therapy, especially among patients …

Lung adenocarcinoma (LUAD), the most common type of cancer, is hard to diagnose and
has an unfavorable prognosis. Tumor mutation burden (TMB) is a useful predictor and can …

Purpose Lung adenocarcinoma (LUAD) is the predominant subtype of lung cancer, with
increasing evidence showing clinical benefits of immunotherapy. However, a lack of …

Background: With the rapid development of immunotherapy for solid tumors, the exploration
of immune characteristics becomes more and more important. Due to the high morbidity and …

Background Lung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year
overall survival rate of lower than 20% among patients with advanced lung cancer. This …

Background. Lung adenocarcinoma (LUAD) is the commonest of the subtypes of lung
cancer histologically. For this study, we intended to analyze the expression profiling of the …

Background Lung cancer has become the most common cancer type and caused the most
cancer deaths. Lung adenocarcinoma (LUAD) is one of the major type of lung cancer. This …